Physician profile
Alejandro Bevacqua
NPI 1487670865
$2,456.72
in general payments reported to CMS, 2019-2025
20 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $85.53 · 2021: $459 · 2022: $294 · 2023: $291 · 2024: $521 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $458.12 | 2019-2025 | Argos, Tryptyr, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $312.71 | 2022-2025 | Envista Mx60 Iol, Infuse, Miebo |
| Tarsus Pharmaceuticals, INC. | $184.49 | 2024-2025 | Xdemvy |
| Allergan, INC. | $183.28 | 2020-2022 | |
| New World Medical,INC. | $155.20 | 2021-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Abbvie INC. | $153.89 | 2023-2025 | Durysta |
| Dompe US, INC. | $142.93 | 2023-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $131.49 | 2019-2025 | Cequa |
| Ocular Therapeutix, INC. | $124.60 | 2021-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $112.19 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $88.74 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Oyster Point Pharma, INC. | $83.36 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $65.94 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $48.65 | 2021-2022 | |
| Sight Sciences, INC. | $48.50 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $43.17 | 2019 | |
| Omeros Corporation | $30.94 | 2019-2021 | |
| Biotissue Holdings INC. | $30.27 | 2024 | |
| Aerie Pharmaceuticals, INC. | $29.91 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Bevacqua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.